期刊文献+
共找到1,026篇文章
< 1 2 52 >
每页显示 20 50 100
Vitamin D,selenium,and antidiabetic drugs in the treatment of type 2 diabetes mellitus with Hashimoto's thyroiditis 被引量:2
1
作者 Fen Feng Bin Zhou +3 位作者 Ci-La Zhou Ping Huang Gang Wang Kuang Yao 《World Journal of Diabetes》 SCIE 2024年第2期209-219,共11页
BACKGROUND Diabetes and thyroiditis are closely related.They occur in combination and cause significant damage to the body.There is no clear treatment for type-2 diabetes mellitus(T2DM)with Hashimoto's thyroiditis... BACKGROUND Diabetes and thyroiditis are closely related.They occur in combination and cause significant damage to the body.There is no clear treatment for type-2 diabetes mellitus(T2DM)with Hashimoto's thyroiditis(HT).While single symptomatic drug treatment of the two diseases is less effective,combined drug treatment may improve efficacy.AIM To investigate the effect of a combination of vitamin D,selenium,and hypoglycemic agents in T2DM with HT.METHODS This retrospective study included 150 patients with T2DM and HT treated at The Central Hospital of Shaoyang from March 2020 to February 2023.Fifty patients were assigned to the control group,test group A,and test group B according to different treatment methods.The control group received low-iodine diet guidance and hypoglycemic drug treatment.Test group A received the control treatment plus vitamin D treatment.Test group B received the group A treatment plus selenium.Blood levels of markers of thyroid function[free T3(FT3),thyroid stimulating hormone(TSH),free T4(FT4)],autoantibodies[thyroid peroxidase antibody(TPOAB)and thyroid globulin antibody(TGAB)],blood lipid index[low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),triacylglycerol(TG)],blood glucose index[fasting blood glucose(FBG),and hemoglobin A1c(HbA1c)]were measured pre-treatment and 3 and 6 months after treatment.The relationships between serum 25-hydroxyvitamin D3[25(OH)D3]level and each of these indices were analyzed.RESULTS The levels of 25(OH)D3,FT3,FT4,and LDL-C increased in the order of the control group,test group A,and test group B(all P<0.05).The TPOAB,TGAB,TC,TG,FBG,HbA1c,and TSH levels increased in the order of test groups B,A,and the control group(all P<0.05).All the above indices were compared after 3 and 6 months of treatment.Pre-treatment,there was no divergence in serum 25(OH)D3 level,thyroid function-related indexes,autoantibodies level,blood glucose,and blood lipid index between the control group,test groups A and B(all P>0.05).The 25(OH)D3 levels in test groups A and B were negatively correlated with FT4 and TGAB(all P<0.05).CONCLUSION The combination drug treatment for T2DM with HT significantly improved thyroid function,autoantibody,and blood glucose and lipid levels. 展开更多
关键词 Type-2 diabetes mellitus Hashimoto's thyroiditis Vitamin D Selenium agent Hypoglycemic drugs Curative effect
下载PDF
Effect of sitagliptin combined with Yiqi yangyin huoxue decoction on clinical efficacy and hemorheology in early diabetic nephropathy 被引量:1
2
作者 Jun Ling Yan-Hua Yang 《World Journal of Diabetes》 SCIE 2023年第9期1412-1421,共10页
BACKGROUND Early diabetic nephropathy(DN)is a complication of diabetes mellitus.It mainly affects kidney microvessels and glomerular function,and its timely and effective treatment is critical for early DN.However,the... BACKGROUND Early diabetic nephropathy(DN)is a complication of diabetes mellitus.It mainly affects kidney microvessels and glomerular function,and its timely and effective treatment is critical for early DN.However,the effects of treatments comprising simple Western medicine are not optimal.With the promotion and implementation of integrated Chinese and western medicine treatments,remarkable results have been achieved for many diseases.To this end,we explored the clinical efficacy of integrated traditional Chinese and western medicines for the treatment of early DN.AIM To investigate the effect of sitagliptin tablets combined with Yiqi yangyin huoxue decoction on clinical efficacy and hemorheology in patients with early DN.METHODS Through a retrospective analysis,123 patients with early DN were admitted to the endocrinology clinic of the Changzhou NO.7 People’s Hospital from January 2021 to October 2022 and were selected as study subjects.After rigorous screening,100 patients with early DN were enrolled.The control group(CG,n=50)and the observation group(OG,n=50)were divided according to the treatment method.The CG were treated with sitagliptin,and the OG were treated with sitagliptin plus the Yiqi yangyin huoxue decoction.Both groups were treated for 3 mo.For both groups,the baseline data and clinical efficacy were compared,and changes in blood glucose levels,lipid levels,renal function,and hematological indicators before(T0)and after(T1)treatment were assessed.RESULTS The total effective rate for the OG was 94.00%and that of the CG was 80.00%(P<0.05).After treatment(T1),the levels of fasting blood glucose,2 h postprandial glucose,total cholesterol,triacylglycerol,and low-density lipoprotein cholesterol in OG patients were obviously lower than those in the CG(P<0.05),and cystatin C,homocysteine,urinary microalbumin,and blood creatinine values in OG patients were also obviously lower than those in the CG(P<0.05);erythrocyte deposition,plasma viscosity,whole blood high shear viscosity,and whole blood low shear viscosity were markedly lower in OG patients than in the CG(P<0.05).CONCLUSION Sitagliptin combined with Yiqi yangyin huoxue decoction has a remarkable effect when used to treat patients with early DN.Further,it is helpful in improving hemorheological indices and controlling disease progression. 展开更多
关键词 SITAGLIPTIN Yiqi yangyin huoxue decoction Early diabetic nephropathy Renal function Clinical effects HEMORHEOLOGY
下载PDF
Efficacy of Bee Products(Anzer Honey,Pollen and Propolis)in Detection and Healing of Damage Induced by Antidiabetic Drug Vildagliptin/Metformin Hydrochloride in Healthy Human Pancreatic Cells:Cytotoxic,Genotoxic and Biochemical Studies
3
作者 ÖzlemÖzdemir ZinetÇöl Ömer Ertürk 《Current Medical Science》 SCIE CAS 2023年第6期1173-1182,共10页
Background and Objective Although drugs are powerful therapeutic agents,they have a range of side effects.These side effects are sometimes cellular and not clinically noticeable.Vildagliptin/metformin hydrochloride is... Background and Objective Although drugs are powerful therapeutic agents,they have a range of side effects.These side effects are sometimes cellular and not clinically noticeable.Vildagliptin/metformin hydrochloride is one of the most widely used oral antidiabetic drugs with two active ingredients.In this study,we investigated its harmful effects on the metabolic activation system in healthy human pancreatic cells“hTERT-HPNE”,and we aimed to improve these harmful effects by natural products.To benefit from the healing effect,we used the unique natural products produced by the bees of the Anzer Plateau in the Eastern Black Sea Region of Turkey.Methods Cytotoxic and genotoxic effects of the drug were investigated by different tests,such as MTT,flow cytometry-apoptosis and comet assays.Anzer honey,pollen and propolis were analyzed by gas chromatography/mass spectrometry(G/C-MS).A total of 19 compounds were detected,constituting 99.9%of the samples.Results The decrease in cell viability at all drug concentrations was statistically significant compared to the negative control(P<0.05).A statistically significant decrease was detected in the apoptosis caused by vildagliptin/metformin hydrochloride with the supplementation of Anzer honey,pollen and propolis in hTERT-HPNE cells(P<0.05).Conclusion This study can contribute to other studies testing the healing properties of natural products against the side effects of oral antidiabetics in human cells.In particular,Anzer honey,pollen and propolis can be used as additional foods to maintain cell viability and improve heal damage and can be evaluated against side effects in other drug studies. 展开更多
关键词 cell viability hTERT-HPNE Anzer bee products drug side effect diabetes mellitus
下载PDF
Methodological challenges to control for immortal time bias in addressing drug effects in type 2 diabetes
4
作者 Xi-Lin Yang Xiao-Xu Huo Juliana CN Chan 《World Journal of Methodology》 2015年第3期122-126,共5页
There are multiple biases in using observational studies to examine treatment effects such as those from prevalent drug users, immortal time and drug indications. We used renin angiotensin system(RAS) inhibitors and s... There are multiple biases in using observational studies to examine treatment effects such as those from prevalent drug users, immortal time and drug indications. We used renin angiotensin system(RAS) inhibitors and statins as reference drugs with proven efficacies in randomized clinical trials(RCTs) and examined their effectiveness in the prospective Hong Kong Diabetes Registry using adjustment methods proposed in the literature. Using time-dependent exposures to drug treatments yielded greatly inflated hazard ratios(HR) regarding the treatment effects of these drugs for cardiovascular disease(CVD) in type 2 diabetes. These errors were probably due to changing indications to use these drugs during follow up periods, especially at the time of drug commencement making time-dependent analysis extremely problematic. Using time-fixed analysis with exclusion of immortal time and adjustment for confounders at baseline and/or during follow-up periods, the HR of RAS inhibitors for CVD was comparable to that in RCT. The result supported the use of the Registry for performing pharmacoepidemiological analysis which revealed an attenuated low low-density lipoprotein cholesterol related cancer risk with RAS inhibitors. On the other hand, time-fixed analysis with including immortal time and adjustment for confounders at baseline and/or during follow-up periods, the HR of statins for CVD was similar to that in the RCT. Our results highlight the complexity and difficulty in removing these biases. We call for validations of the methods to cope with immortal time and drug use indications before applying them to particular research questions, so to avoid making erroneous conclusions. 展开更多
关键词 Pharmacoepidemiological analysis IMMORTAL TIME BIAS drug effects Prevalent drug user BIAS drug INDICATION BIAS Type 2 diabetes
下载PDF
Treatment of Incipient Diabetic Nephropathy by Clearing Away the Stomach-Heat,Purging the Heart Fire,Strengthening the Spleen and Tonifying the Kidney 被引量:1
5
作者 吴深涛 韩英梅 李静 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2000年第3期172-175,共4页
  It is the view of the authors that accumulation of heat and dampness in the heart and stomach and deficiency of both spleen and kidney with blood stasis would be the main predisposing factors in pathogenesis of in...   It is the view of the authors that accumulation of heat and dampness in the heart and stomach and deficiency of both spleen and kidney with blood stasis would be the main predisposing factors in pathogenesis of incipient diabetic nephropathy. A controlled clinical study of 32 patients treatment with modified recipe of Wang Kentang’s Bai Fu Ling Wan, a proved formula of clearing away the stomach-heat, purging the heart fire, strengthening the stomach and tonifying the kidney, and simultaneously resolving blood stasis and turbid qi was performed. The total effective rate was 93.8%, superior to that in the control group treated with Capoton (59.9%). A marked improvement in symptoms, control of blood glucose level and reduction of urinary protein obtained in the treatment group suggests that this treatment is effective in retarding the development of the disease. 展开更多
关键词 Adult Aged diabetes Mellitus Type 2 diabetic Nephropathies drugs Chinese Herbal Female Humans Male Middle Aged
下载PDF
Research of the clinical efficacy of Qiming Granule in treatment of diabetic nephropathy by meta-analysis
6
作者 Ning Liu Tao He +1 位作者 Chuanxin Liu Jianmei Huang 《TMR Modern Herbal Medicine》 CAS 2021年第3期37-48,共12页
Objective:To systematically evaluate the clinical efficacy of Qiming Granule combined with conventional therapy in improving diabetic nephropathy.Methods:The Chinese and English databases such as Wanfang,VIP,CNKI,PubM... Objective:To systematically evaluate the clinical efficacy of Qiming Granule combined with conventional therapy in improving diabetic nephropathy.Methods:The Chinese and English databases such as Wanfang,VIP,CNKI,PubMed,Cochrane library and Web of Science database were searched.The searching time was from the database was established to March 1,2021.The papers were screened strictly according to the inclusion and exclusion criteria.The inclusion risk assessment tool provided by the Cochrane Collaboration was used to evaluate the included literature,the data was analyzed using STATA 12.0 software.Results:Twelve papers were included,involving 1369 patients.The results of meta-analysis showed that Qiming Granule combined with conventional treatment had statistical significance in improving the clinical total effective rate[RR=1.24,95%CI(1.12,1.36)],urinary albumin excretion rate[SMD=-2.68,95%CI(-3.86,-1.50)],creatinine[SMD=-1.46,95%CI(-1.84,-1.08)],urea nitrogen[SMD=-2.61,95%CI(-3.85,-1.36)],fasting blood glucose[SMD=-1.17,95%CI(-2.03,-0.31)]and cystatin C[SMD=-3.26,95%CI(-4.65,-1.87)]of patients with diabetic nephropathy.Conclusion:The combination of conventional therapy and Qiming Granule can improve the clinical effect for diabetic nephropathy.However,due to the low level of overall literature evidence,high risk and some kind of publication bias,it still needs more high-quality and large-scale clinical studies for further verification. 展开更多
关键词 Qiming Granule diabetic nephropathy META-ANALYSIS Clinical effects Randomized Controlled Trials
下载PDF
A CLINICAL TRIAL OF TANG SHEN NING FOR TREATMENT OF DIABETIC NEPHROPATHY
7
作者 高彦彬 吕仁和 +6 位作者 王秀琴 庚及弟 任可 王越 赵进喜 于秀辰 陈丁生 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 1998年第4期247-252,共6页
This paper reports the clinical trial of Tang Shen Ning ([symbol: see text], TSN) for treating diabetic nephropathy (incipient and clinical, as divided by Mogensen). The results showed that the total effective rate in... This paper reports the clinical trial of Tang Shen Ning ([symbol: see text], TSN) for treating diabetic nephropathy (incipient and clinical, as divided by Mogensen). The results showed that the total effective rate in treatment group (TSN + western medicine) was 90.0%, and that in the control group (simply with western medicine), 56.7%. TSN plays important roles in decreasing proteinuria and improving renal functions. 展开更多
关键词 Adult Aged Antihypertensive Agents CAPTOPRIL diabetes Mellitus Type 2 diabetic Nephropathies drugs Chinese Herbal Female Humans Male Middle Aged QI Yin Deficiency
全文增补中
益智仁-乌药药对调控PI3K/Akt/mTOR通路介导细胞自噬保护肾小球足细胞的作用机制研究 被引量:4
8
作者 尹德辉 唐诗韵 +2 位作者 吴珠 陈应奇 朱叶 《中华中医药学刊》 CAS 北大核心 2024年第1期30-34,I0004-I0006,共8页
目的研究益智仁-乌药药对通过调控PI3K/Akt/mTOR信号通路促进足细胞自噬治疗糖尿病肾病(Diabetic Nephropathy,DN)的作用。方法60只造模成功的C57BL/KSJ-db/db(以下简称db/db)小鼠随机分为模型组、二甲双胍组、缬沙坦组、益智仁-乌药药... 目的研究益智仁-乌药药对通过调控PI3K/Akt/mTOR信号通路促进足细胞自噬治疗糖尿病肾病(Diabetic Nephropathy,DN)的作用。方法60只造模成功的C57BL/KSJ-db/db(以下简称db/db)小鼠随机分为模型组、二甲双胍组、缬沙坦组、益智仁-乌药药对(低、中、高剂量)组,每组10只;另取10只C57BL/KSJ-db/m(以下简称db/m)小鼠为正常组,正常组和模型组给予生理盐水,治疗组小鼠分别给予相应药物,给药8周后检测小鼠肾脏病理学改变,足细胞自噬体数量、结构及相关蛋白表达。结果与模型组相比,益智仁-乌药药对组可显著减轻糖尿病肾病小鼠肾小球基底膜增厚情况,增加足细胞自噬体数量,显著升高自噬相关蛋白表达(P<0.05),降低PI3K/Akt/mTOR信号通路相关蛋白的表达(P<0.05)。其中益智仁-乌药药对高剂量组各指标改善优于益智仁-乌药低、中剂量组。结论益智仁-乌药药对通过抑制PI3K/Akt/mTOR信号通路激活,提高足细胞自噬水平,减轻足细胞损伤,发挥治疗糖尿病肾病的作用。 展开更多
关键词 益智仁-乌药药对 糖尿病肾病 PI3K/AKT/MTOR 足细胞 自噬
下载PDF
抗VEGF药物联合全视网膜光凝治疗糖尿病视网膜病变的效果和预后分析 被引量:1
9
作者 汤畴旺 张采华 郑上椿 《中国卫生标准管理》 2024年第12期141-144,共4页
目的探讨抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物联合全视网膜光凝(panretinal photocoagulation,PRP)治疗糖尿病视网膜病变的效果和预后分析。方法选取三明市第二医院2020年1月—2023年1月收治的50例糖尿病... 目的探讨抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物联合全视网膜光凝(panretinal photocoagulation,PRP)治疗糖尿病视网膜病变的效果和预后分析。方法选取三明市第二医院2020年1月—2023年1月收治的50例糖尿病视网膜病变者(78眼),以随机数字表法分为2组,各25例(39眼)。对照组患者给予PRP治疗,研究组给予抗VEGF药物联合PRP治疗。比较2组术前、术后恢复指标,统计患者治疗后的不良反应,评价治疗效果。结果术后,2组最佳矫正视力(best correct vision acuity,BCVA)优于术前,视网膜新生血管(retinal neovascularization,RNV)面积、中央视网膜厚度(central retinal thickness,CRT)低于术前,且研究组BCVA高于对照组;RNV面积、CRT低于对照组,差异有统计学意义(P<0.05);研究组并发症总发生率为5.13%,低于对照组的23.08%,差异有统计学意义(P<0.05);研究组治疗总有效率为94.97%,高于对照组的79.49%,差异有统计学意义(P<0.05)。结论糖尿病视网膜病变以抗VEGF药物联合PRP治疗可改善术后BCVA,减少RNV面积、CRT,降低并发症发生率,提升治疗效果。 展开更多
关键词 抗VEGF药物 全视网膜光凝 糖尿病视网膜病变 中央视网膜新生血管面积 治疗效果 预后效果
下载PDF
沙库巴曲缬沙坦联合硝苯地平控释片治疗2型糖尿病肾病合并高血压患者的临床效果 被引量:1
10
作者 陆勇良 林秋伟 +3 位作者 韦广 何赣维 汤展 刘成彬 《中国医药科学》 2024年第3期124-127,共4页
目的 探究沙库巴曲缬沙坦联合硝苯地平控释片对2型糖尿病肾病合并高血压患者的治疗效果。方法 选取2022年1月至2023年1月高州市人民医院收治的2型糖尿病肾病合并高血压患者100例,以随机数表法将其分为两组,对照组给予缬沙坦80 mg qd与... 目的 探究沙库巴曲缬沙坦联合硝苯地平控释片对2型糖尿病肾病合并高血压患者的治疗效果。方法 选取2022年1月至2023年1月高州市人民医院收治的2型糖尿病肾病合并高血压患者100例,以随机数表法将其分为两组,对照组给予缬沙坦80 mg qd与硝苯地平控释片30 mg qd降压治疗,观察组给予沙库巴曲缬沙坦200 mg qd与硝苯地平控释片30 mg qd降压治疗,比较两组患者治疗前后血压、血糖、肾功能指标、血管内皮相关因子及炎性因子变化情况,同时观察两组患者不良反应的发生情况。结果 观察组治疗后血压、空腹血糖、糖化血红蛋白低于对照组,差异有统计学意义(P <0.05);观察组治疗后肌酐、尿素氮、尿微量白蛋白、胱抑素C水平低于对照组,差异有统计学意义(P <0.05);观察组治疗后血管紧张素Ⅱ、超敏C反应蛋白、白介素-6水平低于对照组,差异有统计学意义(P <0.05);两组不良反应总发生率比较,差异无统计学意义(P> 0.05)。结论 沙库巴曲缬沙坦联合硝苯地平控释片对于2型糖尿病肾病合并高血压的患者的治疗效果较好,可较好地控制血压和血糖水平,减缓患者肾功能衰竭进程。 展开更多
关键词 沙库巴曲缬沙坦 硝苯地平控释片 2型糖尿病肾病合并高血压 临床效果
下载PDF
肾小管及肾小球标志物在2型糖尿病患者不同肾损伤阶段诊断价值的研究
11
作者 张琳 谢荣荣 +5 位作者 杨芳远 李眉 罗莎 万晓华 田玮 杨金奎 《首都医科大学学报》 CAS 北大核心 2024年第3期429-437,共9页
目的探讨肾小管及肾小球相关标志物在2型糖尿病(type 2 diabetes mellitus,T2DM)患者不同肾损伤阶段的诊断价值。方法选取于2018年4月1日至2019年10月31日入住首都医科大学附属北京同仁医院内分泌科的T2DM患者272例,完善临床生化指标及... 目的探讨肾小管及肾小球相关标志物在2型糖尿病(type 2 diabetes mellitus,T2DM)患者不同肾损伤阶段的诊断价值。方法选取于2018年4月1日至2019年10月31日入住首都医科大学附属北京同仁医院内分泌科的T2DM患者272例,完善临床生化指标及尿蛋白四项:尿微量白蛋白/肌酐(urinary albumin to creatinine ratio,ACR)、α1-微球蛋白/肌酐(urinary α1-microglobulin to creatinine ratio,UA1CR)、免疫球蛋白G/肌酐(urinary immunoglobulin G to creatinine ratio,UIGG)、转铁蛋白/肌酐(urinary transferrin to creatinine ratio,UTRF);进行眼底照相、核医学99mTc-EC检测肾有效血浆流量(effective renal plasma flow,ERPF)和99mTc-DTPA检测肾小球滤过率(glomerular filtration rate,GFR)。根据ACR和眼底检查结果分为4组:正常蛋白尿无糖尿病视网膜病变(diabetic retinopathy,DR)132例,即对照组(ACR≤30 mg/g);正常蛋白尿合并DR 32例,为糖尿病肾病(diabetic kidney disease,DKD)前期组;微量蛋白尿组78例(30<ACR≤300 mg/g)和大量蛋白尿组30例(ACR>300 mg/g)。比较四组间尿蛋白四项和ERPF、GFR的水平,通过受试者工作特征(receiver operating characteristic,ROC)曲线评价上述各指标在不同肾损伤阶段的诊断价值。结果尿蛋白四项和ERPF、GFR的水平在不同组间差异有统计学意义(P<0.05)。在尿蛋白正常组中,DR组中肾小管功能标志物UA1CR较对照组明显升高(P<0.01);肾小球功能标志物ACR、UTRF和GFR在两组间差异无统计学意义(P>0.05),DR组UIGG较对照组升高(P<0.01)。在微量蛋白尿组和大量蛋白尿组,尿蛋白四项随肾损伤程度增加而增加,而ERPF和GFR随肾损伤程度增加而降低。ROC曲线分析显示,在尿蛋白排出正常的T2DM患者中合并DR组中肾小管功能标志物UA1CR和ERPF的曲线下面积(area under the curve,AUC)分别为68.2%(P<0.01)和60.5%(P<0.05),而肾小球功能标志物ACR和GFR的AUC均小于60%,差异无统计学意义(P>0.05)。尿蛋白四项及GFR在微量和大量蛋白尿组的AUC均大于60%(P<0.05),ERPF在大量蛋白尿组AUC为67.2%(P<0.05)。结论T2DM极早期微血管改变即ACR正常仅有DR时,肾小管标志物UA1CR先于肾小球标志物ACR和GFR发生变化。肾损伤早期,肾小管标志物诊断效能优于肾小球;肾损伤后期,肾小球标志物诊断效能优于肾小管。提示DKD肾小管功能的改变可能早于肾小球。 展开更多
关键词 糖尿病肾病 肾小管标志物 Α1-微球蛋白 肾有效血浆流量 ROC曲线下面积
下载PDF
糖肾康饮治疗气阴两虚兼瘀型早期糖尿病肾病临床观察
12
作者 郅扶旻 薛影 +3 位作者 徐洪涛 马建 李永华 赵娜 《西部中医药》 2024年第9期143-146,共4页
目的:观察糖肾康饮对气阴两虚兼瘀型早期糖尿病肾病患者的临床疗效。方法:将72例气阴两虚兼瘀型早期糖尿病肾病患者按随机数字表法分为治疗组和对照组各36例。对照组进行基础治疗,治疗组在基础治疗的同时口服自拟方糖肾康饮,观察两组患... 目的:观察糖肾康饮对气阴两虚兼瘀型早期糖尿病肾病患者的临床疗效。方法:将72例气阴两虚兼瘀型早期糖尿病肾病患者按随机数字表法分为治疗组和对照组各36例。对照组进行基础治疗,治疗组在基础治疗的同时口服自拟方糖肾康饮,观察两组患者血糖、肾功能指标及临床疗效。结果:治疗后两组患者空腹血糖(fasting blood glueose,FPG)、餐后2小时血糖(2 hour plasma blood glucose,2h PG)、糖化血红蛋白(glycated haemoglobin,HbA1c)水平、尿微量蛋白排泄率(urine albumin excretionrate,UAER)与微量白蛋白(microalbuminuria,mALB)水平均较治疗前降低(P<0.05),治疗组低于对照组(P<0.05);临床疗效治疗组优于对照组(P<0.05)。结论:基础治疗的同时口服自拟方糖肾康饮可提高气阴两虚兼瘀型早期糖尿病肾病患者中医证候临床疗效,降低血糖,保护肾功能,延缓糖尿病肾病病情进展。 展开更多
关键词 糖尿病肾病 气阴两虚兼瘀 糖肾康饮 临床疗效
下载PDF
糖尿病肾病患者以参芪地黄汤辨证加减治疗的预后质量分析
13
作者 王新虎 《糖尿病新世界》 2024年第15期174-177,共4页
目的探讨糖尿病肾病患者以参芪地黄汤辨证加减治疗的预后质量。方法选取2023年1月—2024年1月济南市历城区中医医院诊治的75例糖尿病肾病患者为研究对象,根据不同治疗方法分为两组,对照组(38例)以盐酸贝那普利片+恩格列净片治疗;研究组... 目的探讨糖尿病肾病患者以参芪地黄汤辨证加减治疗的预后质量。方法选取2023年1月—2024年1月济南市历城区中医医院诊治的75例糖尿病肾病患者为研究对象,根据不同治疗方法分为两组,对照组(38例)以盐酸贝那普利片+恩格列净片治疗;研究组(37例)在对照组基础上加用参芪地黄汤治疗。比较两组用药疗效、血糖、肾功能指标改变情况。结果研究组治疗有效率为91.89%(34/37),高于对照组的73.68%(28/38),差异有统计学意义(χ^(2)=4.337,P<0.05)。用药后,两组空腹血糖、餐后2 h血糖、糖化血红蛋白均较用药前降低,且研究组均低于对照组,差异有统计学意义(P均<0.05)。用药后,两组血肌酐、胱抑素C、血尿素氮、肾损伤分子-1均较用药前降低,且研究组均低于对照组,差异有统计学意义(P均<0.05)。结论糖尿病肾病以参芪地黄汤进行辨证治疗,对血糖、肾功能的调控效果更理想,可强化临床整体治疗效果。 展开更多
关键词 糖尿病肾病 参芪地黄汤 辨证加减 用药疗效
下载PDF
血液透析护理个体化指导对糖尿病肾病透析患者自体动静脉内瘘维护效果
14
作者 乔书琴 《智慧健康》 2024年第1期211-215,共5页
目的对糖尿病肾病透析患者接受个体化指导的价值进行分析。方法选取2021年6月—2022年12月本院收治的76例糖尿病肾病透析患者为研究对象,并按照护理方法的不同分为对照组(n=38)、实验组(n=38)两组,分别予以常规护理和个体化指导,并对比... 目的对糖尿病肾病透析患者接受个体化指导的价值进行分析。方法选取2021年6月—2022年12月本院收治的76例糖尿病肾病透析患者为研究对象,并按照护理方法的不同分为对照组(n=38)、实验组(n=38)两组,分别予以常规护理和个体化指导,并对比护理效果。结果相较于对照组,实验组的并发症发生率及焦虑和抑郁评分更低、患者满意度更高、临床症状缓解时间及护理时间更短,组间对比差异具有统计学意义(P<0.05)。结论在糖尿病肾病患者进行血液透析治疗期间,予以护理个体化指导,不仅能够改善其睡眠质量及不良情绪、缩短临床症状缓解时间及护理时间,还能够减少各种并发症的出现,进一步提升患者的满意程度,从而保证临床治疗的有效性及安全性,值得推广。 展开更多
关键词 糖尿病肾病 血液透析 个体化指导 自体动静脉内瘘 维护效果
下载PDF
糖尿病并发症发病机制及治疗药物研究进展
15
作者 张云琪 许宵钰 +2 位作者 马郭薇 孙晓波 罗云 《中国药理学通报》 CAS CSCD 北大核心 2024年第10期1808-1813,共6页
近几十年来,糖尿病患病率逐年上升,其引起的一系列并发症主要包括糖尿病心肌病、视网膜病变、肾病、骨质疏松症和神经病变等。这些并发症的发病机制仍然很不明朗,同时也迫切需要一些治疗药物满足临床需求。该综述总结了近5年来各类糖尿... 近几十年来,糖尿病患病率逐年上升,其引起的一系列并发症主要包括糖尿病心肌病、视网膜病变、肾病、骨质疏松症和神经病变等。这些并发症的发病机制仍然很不明朗,同时也迫切需要一些治疗药物满足临床需求。该综述总结了近5年来各类糖尿病并发症的发病机制、目前广受关注的标志物与主流治疗药物,以期为糖尿病并发症药物研发提供参考。 展开更多
关键词 糖尿病心肌病 糖尿病视网膜病变 糖尿病肾病 糖尿病骨质疏松症 糖尿病神经病变 发病机制 标志物 治疗药物
下载PDF
参芪固肾方联合恩格列净治疗2型糖尿病肾脏病G3aA2期患者的临床观察
16
作者 赵静 袁怡 +2 位作者 周鑫 陆俊锋 方朝晖 《中国临床保健杂志》 CAS 2024年第4期495-498,共4页
目的探讨参芪固肾方联合恩格列净治疗2型糖尿病肾脏病G3aA2期患者的临床应用效果。方法选取2022年2月至2023年12月六安市中医院内分泌科收治的60例2型糖尿病肾脏病G3aA2期患者,利用随机数字表法分为对照组30例、观察组30例。每组患者均... 目的探讨参芪固肾方联合恩格列净治疗2型糖尿病肾脏病G3aA2期患者的临床应用效果。方法选取2022年2月至2023年12月六安市中医院内分泌科收治的60例2型糖尿病肾脏病G3aA2期患者,利用随机数字表法分为对照组30例、观察组30例。每组患者均开展膳食干预、有效控制血糖及血压、调脂等治疗措施,2组患者全部口服恩格列净,观察组患者再服用参芪固肾方。记录每组患者的血肌酐(Cr)、估算肾小球滤过率(eGFR)、尿视黄醇结合蛋白(URBP)、尿β-N-乙酰氨基葡萄糖苷酶(UNAG)、血清β2-微球蛋白(β2-MG)、尿白蛋白与尿肌酐比值(UACR)、中医证候积分等变化。结果观察组比对照组更突显出临床疗效优势(P<0.05)。组间相比:观察组的Cr、URBP、UNAG、β2-MG、UACR、中医证候积分较对照组降低(均P<0.05),eGFR较对照组提高(P<0.05)。组内相比分析:对照组治疗后的URBP、UNAG、β2-MG比治疗前低(P<0.05)。观察组治疗后的Cr、URBP、UNAG、β2-MG、UACR、中医证候积分比治疗前低(P<0.05),eGFR比治疗前高(P<0.05)。结论参芪固肾方联合恩格列净治疗2型糖尿病肾脏病G3aA2期患者疗效较好。 展开更多
关键词 糖尿病肾脏病 降血糖药 中草药 肾小球滤过率
下载PDF
复方鱼腥草提取物对2型糖尿病大鼠肾脏组织中Sirt1/PGC-1α通路的影响
17
作者 沈越 孙靖烨 +1 位作者 修彦凤 王海颖 《中药新药与临床药理》 CAS CSCD 北大核心 2024年第4期493-499,共7页
目的探讨复方鱼腥草提取物(牛蒡子及鱼腥草的挥发油、水提物、醇提物的混合物)对2型糖尿病大鼠肾脏组织中Sirt1/PGC-1α通路的影响。方法将SD大鼠随机分为正常组、模型组、罗格列酮组(0.3 mg·kg^(-1))、白藜芦醇组(0.12 g·kg^... 目的探讨复方鱼腥草提取物(牛蒡子及鱼腥草的挥发油、水提物、醇提物的混合物)对2型糖尿病大鼠肾脏组织中Sirt1/PGC-1α通路的影响。方法将SD大鼠随机分为正常组、模型组、罗格列酮组(0.3 mg·kg^(-1))、白藜芦醇组(0.12 g·kg^(-1))及复方鱼腥草提取物组(4.5 g·kg^(-1)),每组10只。采用高糖高脂饲料喂养4周联合小剂量腹腔注射1%链脲佐菌素(STZ,30 mg·kg^(-1))复制2型糖尿病大鼠模型。检测各组大鼠24 h尿蛋白、24 h尿白蛋白、尿肌酐以及血清肌酐水平,计算肌酐清除率、肾脏指数。采用HE染色法观察肾脏组织病理形态学变化;免疫组化法检测肾脏组织中Sirt1表达水平;Western Blot法检测大鼠肾皮质中Sirt1、PGC-1α蛋白表达水平。结果与正常组比较,给药4、8周后,模型组大鼠的24 h尿蛋白及尿白蛋白水平、肌酐清除率、肾脏指数均明显升高(P<0.05);肾小球体积明显增大,可见肾间质伴有炎性细胞浸润,系膜区可见明显扩张;免疫组化显示肾脏组织中的Sirt1表达显著下调(P<0.01);肾皮质中Sirt1、PGC-1α蛋白表达均明显下调(P<0.05)。与模型组比较,复方鱼腥草提取物组大鼠的24 h尿蛋白及尿白蛋白水平、肌酐清除率、肾脏指数均明显降低(P<0.05);肾小球增大、系膜增生与基质聚积均有明显改善;免疫组化显示肾脏组织中的Sirt1表达显著上调(P<0.01);肾皮质中Sirt1、PGC-1α蛋白表达均明显上调(P<0.05,P<0.01)。结论复方鱼腥草提取物对2型糖尿病大鼠的早期肾脏损伤具有保护作用,其机制可能与上调肾皮质中Sirt1/PGC-1α通路有关。 展开更多
关键词 复方鱼腥草提取物 2型糖尿病 糖尿病肾病 肾脏保护作用 Sirt1/PGC-1α通路 大鼠
下载PDF
黄葵胶囊联合司美格鲁肽治疗老年糖尿病肾病的临床疗效分析
18
作者 李雨涵 李达 吴桓宇 《实用老年医学》 CAS 2024年第10期1007-1010,1015,共5页
目的分析黄葵胶囊联合司美格鲁肽治疗老年糖尿病肾病的临床疗效。方法选取2021年6月至2023年8月在本院就诊的老年糖尿病肾病病人102例,采用随机数表法将其分成对照组和研究组,各51例。对照组采用司美格鲁肽治疗,研究组在对照组的基础上... 目的分析黄葵胶囊联合司美格鲁肽治疗老年糖尿病肾病的临床疗效。方法选取2021年6月至2023年8月在本院就诊的老年糖尿病肾病病人102例,采用随机数表法将其分成对照组和研究组,各51例。对照组采用司美格鲁肽治疗,研究组在对照组的基础上采用黄葵胶囊治疗。2组均治疗3个月。对比2组血糖指标、肾功能指标、临床疗效、炎症反应及不良反应。结果治疗后,2组HbA1c、餐后2 h血糖(2hPPG)、FPG水平均显著降低(P<0.05),但2组间差异没有统计学意义(P>0.05)。治疗后,2组血肌酐、尿微量白蛋白与尿肌酐比值(UACR)、24 h尿蛋白定量(24hUTP)均显著降低(P<0.05),且研究组显著低于对照组(P<0.05)。研究组总有效率高于对照组(90.20%比72.55%,P<0.05)。治疗后,2组血清转化生长因子β(TGF-β)、细胞黏附分子-1(ICAM-1)、高迁移率族蛋白B1(HMGB1)水平均降低(P<0.05),且研究组下降更显著(P<0.05)。2组间总不良反应发生率差异没有统计学意义(P>0.05)。结论司美格鲁肽联合黄葵胶囊可保护老年糖尿病肾病病人肾功能,减轻炎症反应,维持病人血糖稳定,疗效显著且安全性良好。 展开更多
关键词 黄葵胶囊 司美格鲁肽 老年人 糖尿病肾病 临床疗效 安全性
下载PDF
血必净注射液防治糖尿病肾病的研究进展
19
作者 高正为 汪兰兰 +1 位作者 林洪 任林 《医学综述》 CAS 2024年第12期1502-1506,共5页
近年来,糖尿病肾病(DN)的发病率和死亡率呈升高趋势。目前,临床上DN以西医治疗为主,但仍缺乏行之有效的治疗药物。中医药以其系统性、毒副作用小等优点,在DN的治疗中发挥重要作用。中药复方制剂血必净注射液在DN临床治疗中具有良好的疗... 近年来,糖尿病肾病(DN)的发病率和死亡率呈升高趋势。目前,临床上DN以西医治疗为主,但仍缺乏行之有效的治疗药物。中医药以其系统性、毒副作用小等优点,在DN的治疗中发挥重要作用。中药复方制剂血必净注射液在DN临床治疗中具有良好的疗效。探索血必净注射液在DN治疗中的应用情况,包括单独使用、与西药联合使用以及单味药材在DN治疗中的作用,可为血必净注射液在DN患者中的临床应用和基础研究提供参考依据。 展开更多
关键词 糖尿病肾病 血必净 作用机制 药物治疗
下载PDF
基于NF-κB信号通路研究当归芍药散对糖尿病肾病大鼠肾脏的保护作用及其机制
20
作者 夏振忠 宋恩峰 《医药导报》 CAS 北大核心 2024年第8期1205-1211,共7页
目的基于核因子(NF)-κB信号通路研究当归芍药散对糖尿病肾病(DN)大鼠肾脏的保护作用及其可能的通路机制。方法选择SPF级健康雄性SD大鼠,采用二联法(高脂高糖饮食+腹腔注射链脲佐菌素)诱导建立早期DN大鼠模型,随机分为模型对照组、当归... 目的基于核因子(NF)-κB信号通路研究当归芍药散对糖尿病肾病(DN)大鼠肾脏的保护作用及其可能的通路机制。方法选择SPF级健康雄性SD大鼠,采用二联法(高脂高糖饮食+腹腔注射链脲佐菌素)诱导建立早期DN大鼠模型,随机分为模型对照组、当归芍药散组、厄贝沙坦组,同时设置空白组作为对照,各组给予相应的药物灌胃,分别干预4周。实验结束后记录大鼠体质量、随机血糖(GLU)、24 h饮水量及24 h尿量,分别对大鼠24 h尿蛋白、血肌酐值(Scr)、尿素氮(BUN)、肾脏肥大指数(KW/BW)等各项生理生化指标进行检测;对肾脏行苏木精-伊红(HE)、过碘酸希夫(PAS)染色,光镜下观察肾组织病理形态改变;酶联免疫吸附测定(ELISA)法检测血清中TNF-ɑ、IL-1β、IL-6炎症因子变化;免疫组化法检测肾脏组织中NF-κB蛋白的阳性表达。结果与空白对照组比较,模型对照组大鼠肾脏体积、KW/BW、GLU、24 h尿蛋白定量、24 h饮水量、24 h尿量、Scr、BUN、血清中TNF-ɑ、IL-1β、IL-6水平及肾脏组织NF-κB阳性表达升高(P<0.05),而体质量下降(P<0.05),且肾脏组织病理损害明显;与模型对照组比较,当归芍药散组大鼠肾脏体积、KW/BW、GLU、24 h尿蛋白定量、24 h饮水量、24 h尿量、Scr、血清中TNF-ɑ、IL-1β、IL-6水平及肾脏组织NF-κB阳性表达显著降低(P<0.05),而体质量增加(P<0.05),且肾脏组织病理损害有所缓解。结论当归芍药散可通过下调肾脏组织中炎症信号通路NF-κB蛋白的表达,减少TNF-ɑ、IL-1β、IL-6炎性细胞因子的释放,发挥对DN大鼠的肾脏保护作用,这可能是当归芍药散治疗DN的重要机制。 展开更多
关键词 当归芍药散 糖尿病肾病 NF-ΚB信号通路 保护作用
下载PDF
上一页 1 2 52 下一页 到第
使用帮助 返回顶部